Related Experiment Video
Updated: Jun 12, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation
L Endo-Munoz1, A Cumming, S Sommerville
1The University of Queensland, Diamantina Institute for Cancer, Immunology and Metabolic Medicine, Level 4, R Wing, Princess Alexandra Hospital, Queensland 4102, Australia.
Background:
Osteosarcoma (OS) is the most common primary bone tumour in children and adolescents. Patients who respond poorly to chemotherapy have a higher risk of metastatic disease and 5-year survival rates of only 10-20%. Therefore, identifying molecular targets that are specific for OS, or more specifically, metastatic OS, will be critical to the development of new treatment strategies to improve patient outcomes.
Methods:
We performed a transcriptomic analysis of chemo-naive OS biopsies and non-malignant bone biopsies to identify differentially expressed genes specific to OS, which could provide insight into OS biology and chemoresistance.
Results:
Statistical analysis of the OS transcriptomes found differential expression of several metallothionein family members, as well as deregulation of genes involved in antigen presentation. Tumours also exhibited significantly increased expression of ID1 and profound down-regulation of S100A8, highlighting their potential as therapeutic targets for OS. Finally, we found a significant correlation between OS and impaired osteoclastogenesis and antigen-presenting activity. The reduced osteoclastogenesis and antigen-presenting activity were more profound in the chemoresistant OS samples.
Conclusion:
Our results indicate that OS displays gene signatures consistent with decreased antigen-presenting activity, enhanced chemoresistance, and impaired osteoclastogenesis. Moreover, these alterations are more pronounced in chemoresistant OS tumour samples.
Insights
Osteosarcoma (OS) exhibits gene signatures linked to reduced antigen presentation and impaired osteoclastogenesis. These molecular changes are more pronounced in chemoresistant OS, suggesting novel therapeutic targets for this bone cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Osteosarcoma (OS) is a primary bone cancer in children and adolescents.
- Poor responders to chemotherapy face high metastatic risk and low survival rates (10-20%).
- Identifying specific molecular targets for OS, especially metastatic forms, is crucial for improved treatments.
Purpose of the Study:
- To identify molecular targets specific to osteosarcoma (OS).
- To understand the molecular basis of chemoresistance in OS.
- To discover potential therapeutic targets for improving patient outcomes.
Main Methods:
- Transcriptomic analysis of chemo-naive OS biopsies and non-malignant bone biopsies.
- Identification of differentially expressed genes in OS.
- Statistical analysis of gene expression patterns.
Main Results:
- Differential expression of metallothionein family members and antigen presentation genes in OS.
- Increased ID1 and decreased S100A8 expression observed in OS tumors.
- Correlation between OS and impaired osteoclastogenesis and antigen-presenting activity, more pronounced in chemoresistant samples.
Conclusions:
- OS exhibits gene signatures associated with decreased antigen-presenting activity and impaired osteoclastogenesis.
- Enhanced chemoresistance is a key feature of OS.
- These molecular alterations are more pronounced in chemoresistant OS, indicating potential therapeutic vulnerabilities.
